Global reports of takotsubo (stress) cardiomyopathy following COVID-19 vaccination: a systematic review and meta-analysis
preprint
OA: gold
CC-BY-4.0
Abstract
Concerns have been raised recently about takotsubo cardiomyopathy (TCM) after receiving COVID-19 vaccines, particularly the messenger RNA (mRNA) vaccines. The goal of this study was to compile case reports to provide a comprehensive overview of takotsubo cardiomyopathy (TCM) associated with COVID-19 vaccines. A systematic literature search was conducted in PubMed, Scopus, Embase, Web of Science, and Google Scholar between 2020 and June 1, 2022. The study included individuals who developed cardiac takotsubo cardiomyopathy from receiving COVID-19 vaccinations. Ten studies, including 10 cases, participated in the current systematic review. The mean age was 61.8 years; 90% were female, while 10% were male. 80% of the patients received the mRNA COVID-19 vaccine, while 20% received other types. In addition, takotsubo cardiomyopathy (TCM) occurred in 50% of patients receiving the first dose and another 40% after the second dose of COVID-19 vaccines. Moreover, the mean number of days to the onset of symptoms was 2.62 days. All cases had an elevated troponin test and abnormal ECG findings. The left ventricular ejection fraction (LVEF) was lower than 50% in 90% of patients. In terms of the average length of hospital stay, 50% stayed for 10.2 days, and all cases recovered from their symptoms. In conclusion, takotsubo (stress) cardiomyopathy (TCM) complications associated with COVID-19 vaccination are rare but can be life-threatening. Chest pain should be considered an alarming symptom, especially in those who have received the first and second doses of the COVID-19 vaccine.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (1)
References (61)
- Global Reports of Myocarditis Following COVID-19 Vaccination: A Systematic Review and Meta-Analysis via crossref
- doi:10.1056/nejmoa1406761 via crossref
- doi:10.1016/j.ijcard.2016.02.012 via crossref
- doi:10.1016/j.cpcardiol.2020.100763 via crossref
- doi:10.1007/s42399-020-00557-w via crossref
- doi:10.1161/circulationaha.118.037975 via crossref
- doi:10.1001/jamanetworkopen.2020.14780 via crossref
- doi:10.1016/j.jpsychores.2020.110297 via crossref
- doi:10.5694/mja2.50770 via crossref
- doi:10.1016/j.jconrel.2021.03.043 via crossref
- doi:10.1056/nejmoa2034577 via crossref
- doi:10.1016/j.clim.2021.108786 via crossref
- doi:10.1161/circulationaha.121.056135 via crossref
- doi:10.1001/jama.2021.15072 via crossref
- doi:10.1016/j.hlc.2021.06.521 via crossref
- doi:10.1097/mjt.0000000000001379 via crossref
- doi:10.1007/s13730-021-00657-z via crossref
- doi:10.1016/j.jccase.2021.08.012 via crossref
- doi:10.1136/bcr-2021-246580 via crossref
- doi:10.7759/cureus.15576 via crossref
- doi:10.1016/j.ijcha.2022.101002 via crossref
- doi:10.1016/j.ijsu.2021.105906 via crossref
- doi:10.1136/bmj.j4008 via crossref
- doi:10.1186/s13643-016-0345-y via crossref
- doi:10.1002/ana.26065 via crossref
- doi:10.7759/cureus.23251 via crossref
- doi:10.1016/j.hfc.2016.06.012 via crossref
- doi:10.1056/nejmoa043046 via crossref
- doi:10.1002/rmv.2318 via crossref
- doi:10.1016/j.ejim.2019.02.017 via crossref
- doi:10.1093/eurheartj/ehy076 via crossref
- doi:10.1093/eurheartj/ehy077 via crossref
- doi:10.3390/vaccines9060673 via crossref
- doi:10.1016/j.tifs.2021.12.035 via crossref
- doi:10.1073/pnas.2021726118 via crossref
- doi:10.1016/j.clindermatol.2021.04.001 via crossref
- doi:10.1016/j.jchf.2015.09.013 via crossref
- doi:10.3390/medicina57100997 via crossref
- doi:10.1016/s1473-3099(21)00224-3 via crossref
- doi:10.1016/j.vaccine.2021.02.007 via crossref
- doi:10.1097/mjt.0000000000001379 via crossref
- doi:10.1136/bcr-2021-247291 via crossref
- doi:10.1016/j.hlc.2021.06.521 via crossref
- doi:10.1155/2020/4150291 via crossref
- doi:10.1253/circj.cj-13-1276 via crossref
- doi:10.1093/eurheartj/ehab029 via crossref
- doi:10.1016/j.jacc.2017.12.022 via crossref
- doi:10.1177/2048872615568968 via crossref
- doi:10.1161/circulationaha.112.111591 via crossref
- doi:10.1016/j.ijcard.2016.09.008 via crossref
- doi:10.7326/0003-4819-141-11-200412070-00010 via crossref
- doi:10.1016/j.amsu.2022.103657 via crossref
- doi:10.1016/j.hrtlng.2018.07.016 via crossref
- doi:10.1136/bcr-2021-247291 via crossref
- doi:10.1056/nejmoa043046 via crossref
- doi:10.1038/s41440-021-00798-9 via crossref
- doi:10.1097/mjt.0000000000001379 via crossref
- doi:10.1016/j.ejim.2019.02.017 via crossref
- doi:10.1007/s13730-021-00657-z via crossref
- doi:10.5937/mgiszm2284069q via crossref
- doi:10.1016/j.hfc.2016.06.012 via crossref
Source provenance
- crossref
- last seen: 2026-06-17T06:32:12.012891+00:00
- europepmc
- last seen: 2026-05-19T01:45:01.086888+00:00
- unpaywall
- last seen: 2026-05-21T02:00:01.467718+00:00
License: CC-BY-4.0